NCT05574517 Tubeless Percutaneous Nephrolithotomy Without Reverse Insertion of a Ureteral Catheter
| NCT ID | NCT05574517 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of University of South China |
| Condition | Urinary Calculi |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-10-07 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2022-10-07 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Percutaneous nephrolithotomy(PCNL) is a surgical method for upper urinary calculi. The advent of tubeless PCNL (without indwelling nephrostomy tube) has been proved to be safe and effective in reducing postoperative discomfort, shortening hospitalization time and reducing hospitalization costs. Traditional tubeless PCNL usually involves retrograde insertion of the ureteral catheter, which may cause many ureteral related surgical complications. However, there are few reports on tubeless PCNL without reverse ureteral catheter insertion. The goal of this study is to explore the safety and effectiveness of the tubeless PCNL without reverse ureteral catheter insertion.
Eligibility Criteria
Inclusion Criteria: * Participants who met the the applications of PCNL surgery in the 2019 Chinese Guidelines for the Diagnosis and Treatment of Urological Diseases * Participants who agree to undergo tubeless PCNL * The participants' maximum diameter of the stone should be less than 3.5cm Exclusion Criteria: * Confirmation by computerized tomography (CT) images and blood biochemical indicators of infectious stones or complex staghorn stones * Obvious surgical contraindications, such as severe heart and lung insufficiency, abnormal coagulatory function * Previous PCNL or nephrolithotomy, presence of an indwelling ureteral stent or nephrostomy tube before surgery * Renal trauma or congenital malformation of the urinary system
Contact & Investigator
Mingyong Li, MD
PRINCIPAL INVESTIGATOR
The First Affiliated Hospital of University of South China
Frequently Asked Questions
Who can join the NCT05574517 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Urinary Calculi. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05574517 currently recruiting?
Yes, NCT05574517 is actively recruiting participants. Contact the research team at myli1123@126.com for enrollment information.
Where is the NCT05574517 trial being conducted?
This trial is being conducted at Hengyang, China.
Who is sponsoring the NCT05574517 clinical trial?
NCT05574517 is sponsored by The First Affiliated Hospital of University of South China. The principal investigator is Mingyong Li, MD at The First Affiliated Hospital of University of South China. The trial plans to enroll 200 participants.